BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 17999987)

  • 1. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
    Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
    Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
    Finger EC; Turley RS; Dong M; How T; Fields TA; Blobe GC
    Carcinogenesis; 2008 Mar; 29(3):528-35. PubMed ID: 18174241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
    Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
    Bagnato A; Rosanò L
    Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
    Hempel N; How T; Dong M; Murphy SK; Fields TA; Blobe GC
    Cancer Res; 2007 Jun; 67(11):5231-8. PubMed ID: 17522389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.
    Yang AD; Camp ER; Fan F; Shen L; Gray MJ; Liu W; Somcio R; Bauer TW; Wu Y; Hicklin DJ; Ellis LM
    Cancer Res; 2006 Jan; 66(1):46-51. PubMed ID: 16397214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition.
    Lee HS; Kim C; Kim SB; Kim MG; Park D
    Biochem Biophys Res Commun; 2010 May; 395(4):553-9. PubMed ID: 20398629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells.
    Jungert K; Buck A; von Wichert G; Adler G; König A; Buchholz M; Gress TM; Ellenrieder V
    Cancer Res; 2007 Feb; 67(4):1563-70. PubMed ID: 17308095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory cytokines augments TGF-beta1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I.
    Liu X
    Cell Motil Cytoskeleton; 2008 Dec; 65(12):935-44. PubMed ID: 18792103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells.
    Saito RA; Watabe T; Horiguchi K; Kohyama T; Saitoh M; Nagase T; Miyazono K
    Cancer Res; 2009 Apr; 69(7):2783-91. PubMed ID: 19293183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma.
    Nakajima S; Doi R; Toyoda E; Tsuji S; Wada M; Koizumi M; Tulachan SS; Ito D; Kami K; Mori T; Kawaguchi Y; Fujimoto K; Hosotani R; Imamura M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4125-33. PubMed ID: 15217949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGFbeta Type III and TGFbeta Type II receptors have distinct activities during epithelial-mesenchymal cell transformation in the embryonic heart.
    Boyer AS; Runyan RB
    Dev Dyn; 2001 Aug; 221(4):454-9. PubMed ID: 11500982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple transforming growth factor-beta isoforms and receptors function during epithelial-mesenchymal cell transformation in the embryonic heart.
    Mercado-Pimentel ME; Runyan RB
    Cells Tissues Organs; 2007; 185(1-3):146-56. PubMed ID: 17587820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling.
    Kong B; Michalski CW; Hong X; Valkovskaya N; Rieder S; Abiatari I; Streit S; Erkan M; Esposito I; Friess H; Kleeff J
    Oncogene; 2010 Sep; 29(37):5146-58. PubMed ID: 20581862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
    Räsänen K; Vaheri A
    J Dermatol Sci; 2010 May; 58(2):97-104. PubMed ID: 20399617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
    Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF beta (transforming growth factor beta) receptor type III directs clathrin-mediated endocytosis of TGF beta receptor types I and II.
    McLean S; Di Guglielmo GM
    Biochem J; 2010 Jul; 429(1):137-45. PubMed ID: 20406198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.